These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 26868005)

  • 1. Intravitreal aflibercept for choroidal neovascularization in ocular sarcoidosis.
    Querques L; Querques G; Miserocchi E; Modorati G; Bandello F
    Eur J Ophthalmol; 2016 Aug; 26(5):e124-7. PubMed ID: 26868005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
    Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
    Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
    Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
    Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal aflibercept for the treatment of choroidal neovascularization associated with rubella retinopathy.
    Kiziltoprak H; Yetkin E; Tekin K; Koc M; Akalin İ; Teke MY
    Int Ophthalmol; 2019 Feb; 39(2):477-484. PubMed ID: 29411259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab for extrafoveal choroidal neovascularization after ocular trauma.
    De Benedetto U; Battaglia Parodi M; Knutsson KA; Librando A; Bandello F; Lanzetta P; Iacono P
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):550-2. PubMed ID: 22554238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
    Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J;
    Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
    Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M
    Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
    Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy.
    Broadhead GK; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):979-81. PubMed ID: 25547617
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperreflective Foci Number Correlates with Choroidal Neovascularization Activity in Angioid Streaks.
    Parodi MB; Arrigo A; Romano F; Aragona E; Marchese A; Cicinelli MV; Mercuri S; Bandello F
    Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3314-3319. PubMed ID: 30025095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Hara C; Sawa M; Sayanagi K; Nishida K
    Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.
    Romdhane K; Zola M; Matet A; Daruich A; Elalouf M; Behar-Cohen F; Mantel I
    Br J Ophthalmol; 2020 Jul; 104(7):910-916. PubMed ID: 31615761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.